Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

NCT05534646 is registered in ClinicalTrials.gov with Edwin Posadas, MD as lead sponsor.

NCT NCT05534646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05534646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Lead sponsor
Edwin Posadas, MD
Phase
Phase 2
Overall status
Recruiting
Start date
December 27, 2023
Completion date
January 31, 2028
Enrollment
116 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer